Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2020-02-18 Board/Management Inform…
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 13, 2020. The key content is the announcement of the election of a new director, James V. Cassella, Ph.D., to the Board of Directors of Trevi Therapeutics, Inc. It details his background, compensation, and indemnification agreement. The document does not contain financial statements or quarterly/annual results but focuses on a change in the company's board. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 6297 characters, which is sufficient to contain detailed information about the director appointment. Therefore, the appropriate classification is MANG with high confidence.
2020-02-18 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-18 English
ACQUISITION OF BENEFICIAL OWNERSHIP
Major Shareholding Notification
2020-02-13 English
SC 13G
Major Shareholding Notification
2020-01-31 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 31, 2019, reporting the resignation of a board member, Eran Nadav, Ph.D. The key content is about a change in the company's board of directors. There are no financial statements or detailed financial data, nor is this a report or announcement of financial results. The primary subject is a management/board change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3031 characters, which is short and consistent with a typical 8-K reporting a management change. Therefore, the correct classification is MANG with high confidence.
2020-01-06 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.